This retrospective cohort study assessed the risk of thromboembolic events and major adverse cardiovascular events (MACEs) associated with anti-VEGF therapy in patients with advanced colorectal cancer treated with standard treatment with or without anti-VEGF therapy in Taiwan. This evidence concerns the gene VEGFA and colorectal cancer.